Delayed Surgery Does Not Reduce Transfusion Rates in Low-Energy Hip Fractures on Direct Oral Anticoagulants.


Journal

Journal of orthopaedic trauma
ISSN: 1531-2291
Titre abrégé: J Orthop Trauma
Pays: United States
ID NLM: 8807705

Informations de publication

Date de publication:
01 Apr 2022
Historique:
accepted: 19 08 2021
pubmed: 31 8 2021
medline: 25 3 2022
entrez: 30 8 2021
Statut: ppublish

Résumé

To compare transfusion rates in patients on direct oral anticoagulants (DOACs) with nonanticoagulated patients undergoing hip fracture surgery and, secondarily, to determine whether time to surgery or complications differ between these groups. Multicenter retrospective cohort. Three tertiary care, academic, Level I trauma centers. Acute, operatively treated, low-energy hip fracture patients 55 years of age and older were included. Anticoagulated patients were matched in a 1:2 ratio to "control" nonanticoagulated hip fracture patients using propensity score matching. The primary outcome was incidence of perioperative transfusion. The secondary outcomes included time to surgery, length of stay, and 90-day complications, readmissions, reoperations, and mortality. One hundred thirty-two patients with hip fracture admitted on DOACs were identified (107 factor Xa inhibitors, 25 dabigatran) and were matched to 262 "control" nonanticoagulated patients. There was no difference in overall transfusion rates between anticoagulation and control groups (43.2%; n = 57 DOAC vs. 39.7%; n = 104 control; P = 0.517). The median time from admission to surgery was 41.7 hours in the DOAC group and 26.0 hours in the control group (P < 0.001). There were no differences in 90-day complication, readmission, reoperation, or mortality rates between DOAC and control groups. Comparing DOAC patients undergoing surgery within 24 hours and after 24 hours, there were no differences in transfusion rates (P = 0.558) or overall complication rates (P = 0.179). This study supports growing evidence that DOAC use should not be a determining factor in delaying surgery for patients with hip fracture who are otherwise medically optimized. Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

Identifiants

pubmed: 34456312
doi: 10.1097/BOT.0000000000002251
pii: 00005131-202204000-00003
pmc: PMC8866529
mid: NIHMS1735190
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

172-178

Subventions

Organisme : NIAMS NIH HHS
ID : T32 AR007281
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002384
Pays : United States

Informations de copyright

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors report no conflict of interest.

Références

Barnes GD, Lucas E, Alexander GC, et al. National trends in ambulatory oral anticoagulant use. Am J Med. 2015;128:1300–1305.e2.
Franklin NA, Ali AH, Hurley RK, et al. Outcomes of early surgical intervention in geriatric proximal femur fractures among patients receiving direct oral anticoagulation. J Orthop Trauma. 2018;32:269–273.
Eliasberg CD, Levack AE, Gausden EB, et al. Perioperative use of novel oral anticoagulants in orthopaedic surgery: a critical analysis review. JBJS Rev. 2019;7:e4.
Sennesael AL, Larock AS, Douxfils J, et al. Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. Thromb J. 2018;16:28.
Levy JH. Discontinuation and management of direct-acting anticoagulants for emergency procedures. Am J Emerg Med. 2016;34:14–18.
Papadopoulos DV, Kostas-Agnantis I, Gkiatas I, et al. The role of new oral anticoagulants in orthopaedics: an update of recent evidence. Eur J Orthop Surg Traumatol. 2017;27:573–582.
Shamoun FE, Saadiq RA, Money KS, et al. Periprocedural management of chronically anticoagulated patients: a practical approach to use of novel anticoagulants in orthopedic surgery. Am J Orthop. 2016;45:E161–E166.
Fisher W. Managing hip fracture and lower limb surgery in the emergency setting: potential role of non-vitamin K antagonist oral anticoagulants. J Trauma Acute Care Surg. 2017;82:1112–1121.
Pincus D, Ravi B, Wasserstein D, et al. Association between wait time and 30-day mortality in adults undergoing hip fracture surgery. JAMA. 2017;318:1994–2003.
Simunovic N, Devereaux PJ, Sprague S, et al. Effect of early surgery after hip fracture on mortality and complications: systematic review and meta-analysis. CMAJ. 2010;182:1609–1616.
Leer-Salvesen S, Dybvik E, Ranhoff AH, et al. Do direct oral anticoagulants (DOACs) cause delayed surgery, longer length of hospital stay, and poorer outcome for hip fracture patients? Eur Geriatr Med. 2020;11:563–569.
Ryan DJ, Yoshihara H, Yoneoka D, et al. Delay in hip fracture surgery: an analysis of patient-specific and hospital-specific risk factors. J Orthop Trauma. 2015;29:343–348.
Roberts KC, Brox WT, Jevsevar DS, et al. Management of hip fractures in the elderly. J Am Acad Orthop Surg. 2015;23:131–137.
Hip Fracture: Management. London, United Kingdom: National Institute for Health and Care Excellence (UK); 2017. (NICE Clinical Guidelines, No. 124.) Available at: https://www.ncbi.nlm.nih.gov/books/NBK553768/ .
Frenkel Rutenberg T, Velkes S, Vitenberg M, et al. Morbidity and mortality after fragility hip fracture surgery in patients receiving vitamin K antagonists and direct oral anticoagulants. Thromb Res. 2018;166:106–112.
Taranu R, Redclift C, Williams P, et al. Use of anticoagulants remains a significant threat to timely hip fracture surgery. Geriatr Orthop Surg Rehabil. 2018;9:2151459318764150.
Tran T, Delluc A, de Wit C, et al. The impact of oral anticoagulation on time to surgery in patients hospitalized with hip fracture. Thromb Res. 2015;136:962–965.
Schermann H, Gurel R, Gold A, et al. Safety of urgent hip fracture surgery protocol under influence of direct oral anticoagulation medications. Injury. 2019;50:398–402.
Gosch M, Jacobs M, Bail H, et al. Outcome of older hip fracture patients on anticoagulation: a comparison of vitamin K-antagonists and Factor Xa inhibitors. Arch Orthop Trauma Surg. 2021;141:637–643.
Lott A, Haglin J, Belayneh R, et al. Surgical delay is not warranted for patients with hip fractures receiving non-warfarin anticoagulants. Orthopedics. 2019;42:e331–e335.
Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42:377–381.
Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inf. 2019;95:103208.
Mullins B, Akehurst H, Slattery D, et al. Should surgery be delayed in patients taking direct oral anticoagulants who suffer a hip fracture? A retrospective, case-controlled observational study at a UK major trauma centre. BMJ Open. 2018;8:e020625.
Cohn MR, Levack AE, Trivedi NN, et al. The hip fracture patient on warfarin: evaluating blood loss and time to surgery. J Orthop Trauma. 2017;31:407–413.
Schuetze K, Eickhoff A, Dehner C, et al. Impact of oral anticoagulation on proximal femur fractures treated within 24 hours: a retrospective chart review. Injury. 2019;50:2040–2044.
Oberladstätter D, Voelckel W, Schlimp C, et al. A prospective observational study of the rapid detection of clinically-relevant plasma direct oral anticoagulant levels following acute traumatic injury. Anaesthesia. 2021;76:373–380.
Spahn DR, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care. 2019;23:98.
Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med. 2019;179:1469–1478.
Guay J, Parker MJ, Gajendragadkar PR, et al. Anaesthesia for hip fracture surgery in adults. Cochrane Database Syst Rev. 2016;2:CD000521.
Chen DX, Yang L, Ding L, et al. Perioperative outcomes in geriatric patients undergoing hip fracture surgery with different anesthesia techniques: a systematic review and meta-analysis. Med Baltim. 2019;98:e18220.

Auteurs

Ashley E Levack (AE)

Orthopaedic Trauma Service, Hospital for Special Surgery, New York, NY.

Harold G Moore (HG)

Orthopaedic Trauma Service, Hospital for Special Surgery, New York, NY.

Stephen Stephan (S)

Department of Orthopaedics, Cedars-Sinai Health System, Los Angeles, CA.

Sally Jo (S)

Department of Orthopaedic Surgery, Washington University School of Medicine, St. Louis, MO; and.

Ian Schroeder (I)

Department of Orthopaedics, Cedars-Sinai Health System, Los Angeles, CA.

John Garlich (J)

Department of Orthopaedics, Cedars-Sinai Health System, Los Angeles, CA.

Aidan Hadad (A)

Orthopaedic Trauma Service, Hospital for Special Surgery, New York, NY.

Milton T M Little (MTM)

Department of Orthopaedics, Cedars-Sinai Health System, Los Angeles, CA.

Anna N Miller (AN)

Department of Orthopaedic Surgery, Washington University School of Medicine, St. Louis, MO; and.

Stephen Lyman (S)

Department of Biostatistics, Hospital for Special Surgery, New York, NY.

Joseph Lane (J)

Orthopaedic Trauma Service, Hospital for Special Surgery, New York, NY.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH